The Difficulty of Targeting Cancer Stem Cell Niches
Overview
Authors
Affiliations
Normal stem cell niches typically are identified by their distinctive anatomical features and by association with tissue-specific stem cells. Identifying cancer stem cell (CSC) niches presents a special problem because there are few if any common anatomical features among tumors, and the physical phenotypes that reportedly describe the CSCs as entities may be subject to the host's microenvironment, sex, and tumor stage. Irrespective of a niche's location, the occupant's phenotype, or the precise molecular composition, all niches must do basically the same thing: maintain the activities in a stem cell that define it as such. Therefore, a potentially successful strategy, both for elaborating a molecular and cellular portrait of a CSC niche, and for therapeutically targeting them, is to identify components in the tumor microenvironment that are required for maintaining the functions of self-renewal, differentiation, and quiescence in the face of cytotoxic therapeutic regimens.
Li Y, Fang Y, Lyu Z, Zhu Y, Yang L J Transl Med. 2023; 21(1):686.
PMID: 37784157 PMC: 10546755. DOI: 10.1186/s12967-023-04575-9.
Daunorubicin can eliminate iPS-derived cancer stem cells via ICAD/CAD-independent DNA fragmentation.
Seno A, Mizutani A, Aizawa K, Onoue R, Masuda J, Ochi N Cancer Drug Resist. 2022; 2(2):335-350.
PMID: 35582720 PMC: 8992628. DOI: 10.20517/cdr.2019.01.
Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer.
Nicos M, Krawczyk P Cancers (Basel). 2022; 14(7).
PMID: 35406585 PMC: 8998004. DOI: 10.3390/cancers14071813.
Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective.
Tang Y, Chen Y, Zhang Z, Tang B, Zhou Z, Chen H Pharmaceutics. 2021; 13(12).
PMID: 34959397 PMC: 8708448. DOI: 10.3390/pharmaceutics13122116.
Wang Y, Gong X, Li J, Wang H, Xu X, Wu Y J Nanobiotechnology. 2021; 19(1):397.
PMID: 34838042 PMC: 8627085. DOI: 10.1186/s12951-021-01143-5.